Table 4.
Clinicopathological characteristics of advanced patients who receive anti-EGFR or angiogenesis target therapy and SLC25A18 expression
| Clinic pathological characteristics | Number of Cases (%) | Expression level of SLC25A18 based on IHC score | P-value | |
|---|---|---|---|---|
|
| ||||
| high (%) | low (%) | |||
| Primary tumor site | 0.1566 | |||
| Colon | 61 (59.8) | 31 (50.8) | 30 (49.2) | |
| Rectum | 41 (40.2) | 15 (36.6) | 26 (63.4) | |
| Colon location | 0.2806 | |||
| Right | 30 (29.4) | 16 (53.3) | 14 (46.7) | |
| Left | 72 (70.6) | 30 (41.7) | 42 (58.3) | |
| Gender | 0.8532 | |||
| Male | 70 (68.6) | 32 (45.7) | 38 (54.3) | |
| Female | 32 (31.4) | 14 (43.8) | 18 (56.3) | |
| Age | 0.0034*** | |||
| ≤ 60 | 57 (55.9) | 33 (57.9) | 24 (42.1) | |
| > 60 | 45 (44.1) | 13 (28.9) | 32 (71.1) | |
| Initial stage | 0.7482 | |||
| Advanced | 55 (53.9) | 24 (43.6) | 31 (56.4) | |
| Recurrence | 47 (46.1) | 22 (46.8) | 25 (53.2) | |
| Survival statues | 0.0001**** | |||
| Death | 48 (47.1) | 12 (25.0) | 36 (75.0) | |
| Alive | 54 (52.9) | 34 (63.0) | 20 (37.0) | |
| Primary tumor resection | 0.7482 | |||
| Radical | 55 (53.9) | 24 (43.6) | 31 (56.4) | |
| Palliative | 47 (46.1) | 22 (46.8) | 25 (53.2) | |
| RAS status | 0.0222** | |||
| Mutated | 57 (55.9) | 20 (35.1) | 37 (64.9) | |
| Non-mutated | 45 (44.1) | 26 (57.8) | 19 (42.2) | |
| RAF status | 0.3625 | |||
| Mutated | 7(6.9) | 2 (28.6) | 5 (71.4) | |
| Non-mutated | 95 (93.1) | 44 (46.3) | 51 (53.7) | |
| Anti EGFR† therapy | 0.1064 | |||
| Yes | 40 (39.2) | 22 (55.0) | 18 (45.0) | |
| No | 62 (60.8) | 24 (38.7) | 38 (61.3) | |
| Anti-angiogenesis therapy | 0.049** | |||
| Yes | 55 (53.9) | 20 (36.4) | 35 (63.6) | |
| No | 47 (46.1) | 26 (55.3) | 21 (44.7) | |
| Total | 102 (100) | 46 (45.1) | 56 (54.9) | |
Clinical data were investigated using chi-square test.
†
Abbreviations: EGFR: Epidermal growth factor receptor;
**
P < 0.05;
***
P < 0.01;
****
P < 0.001.